References
- Robertson L. E., Keating M. J. Therapeutic approaches to chronic lymphocytic leukaemia. Tex. Med. 1991; 87: 68–74
- Keating M. J., Estey E., O'Brien S., Kantarjian H., Robertson L. E., Plunkett W. Clinical experience with fludara-bine in leukaemia. Drugs 1994; 47((Suppl. 6))39–49
- Keating M. J., O'Brien S., Robertson L., Huh Y., Kantarjian H., Plunkett W. Chronic lymphocytic leukaemia- correlation of response and survival. Leuk. Lymphoma 1993; 11((Suppl. 2))167–175
- Robertson L. E., Huh Y. O., Butler J. J., Pugh W. C., Hirsch-Ginsberg C., Stass S., Kantarjian H., Keating M. J. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophe-notypic and molecular analysis. Blood 1992; 80: 29–36
- Keating M., Lerner S., Kantarjian H., Freireich E. J., O'Brien S. The serum β2-microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukaemia (CLL). Proceedings of the thirty-seventh meeting of the American Society of Hematology. December, 1995
- Furue H. Topoisomerase inhibitors developing in Japan. Gan To Kagaku Ryoho 1993; 20: 42–49
- Silber R., Degar B., Costin D., Newcomb E. W., Mani M., Rosenberg C. R., Morse L., Drygas J. C., Canellakis Z. N., Potmesil M. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine and camptothecin analogs. Blood 1994; 84: 3440–3446
- O'Brien S., Kantarjian H., Ellis A., Zwelling L., Estey E., Keating M. Topotecan in chronic lymphocytic leukemia. Cancer 1995; 75: 1104–1108
- Bollag W., Holdener E. E. Retinoids in cancer prevention and therapy. Ann. Oncol. 1992; 3: 513–526
- Goodman M. G., Wormsley S. B., Spinosa J. C., Piro L. D. Loxoribine induces chronic lymphocytic leukemic B cells to traverse the cell cycle. Blood 1994; 84: 3457–3464
- al-Katib A., Mohammad R. M., Dan M., Hussein M. E., Akhtar A., Pettit G. R., Sensenbrenner L. L. Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp. Hematol. 1993; 21: 61–65
- Khouri I. F., Keating M. J., Vriesendorp H. M., Reading C. L., Przepiorka D., Huh Y. O., Andersson B. S., van Besien K. W., Mehra R. C., Giralt S. A. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukaemia: preliminary results. J. Clin. Oncol. 1994; 12: 748–758
- Rabinowe S. N., Soiffer R. J., Gribben J. G., Daley H., Freedman A. S., Daley J., Pesek K., Neuberg D., Pinkus G., Leavitt P. R. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B cell chronic lymphocytic leukemia. Blood 1993; 82: 1366–1376
- Vuillier F., Claisse J. F., Vandenvelde C., Travade P., Magnac C., Chevret S., Desablens B., Binet J. L., Dighiero G. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk. Lymphoma 1992; 7: 195–204
- Rugiatelli B., et al. Cancer 1989; 63: 1979–1984